Of the screening group patients, 7.6% ultimately received a diagnosis of a cardiac or valvular disorder.

Now an interntional group of researchers has identified genetic variations that increase the risk for valvular calcification.

Attention will also be given to valvular disease, as the Phase 3 trials excluded patients with significant underlying valve disease.